Research Progress of Twist Gene in Ovarian Cancer

doi:10.3969/j.issn.1007-9572.2016.32.025

Abstract

Abstract: Ovarian cancer is a gynecologic malignant tumor with morbidity in the third place after endometrial cancer and cervical cancer,its fatality rate ranks first in gynecologic malignant tumors.Twist in the transcription factor of basic helix-loop-helix （bHLH） family is highly expressed in ovarian cancer tissues,and its abnormal expression plays an important role in the process of occurrence,development and deterioration of the ovary.After silence processing of Twist gene,proliferation and migration of ovarian carcinoma cells will be obviously affected.By combining recent research results at home and abroad,the paper outlines the latest mechanism of Twist gene in the occurrence and development of ovarian cancer.

Key words: Ovarian neoplasms, Twist gene, Cell proliferation, Review

摘要： 卵巢癌是继子宫内膜癌和宫颈癌发病率居第三位的妇科恶性肿瘤，其病死率居妇科恶性肿瘤之首。碱性螺旋-环-螺旋（bHLH）转录因子家族成员Twist基因在卵巢癌组织中高度表达，其异常表达在卵巢癌的发生、发展及恶化过程中发挥着重要作用。对Twist基因沉默处理后，卵巢癌细胞的增殖及迁移将受到明显的影响。本文通过结合近年来国内外的研究成果，简述了Twist基因在卵巢癌发生、发展中最新的作用机制。

关键词: 卵巢肿瘤, Twist基因, 细胞增殖, 综述

HONG Li, YANG Jiang, XING Hui. Research Progress of Twist Gene in Ovarian Cancer[J]. Chinese General Practice, 2016, 19(32): 4019-4022.

洪莉, 杨将, 邢辉. Twist基因在卵巢癌中的研究进展[J]. 中国全科医学, 2016, 19(32): 4019-4022.

References

［1］张晶晶.Twist相关信号通路与肿瘤的研究进展［J］.中国肿瘤生物治疗杂志,2013,20（1）:124-127. ZHANG J J.Research advance of Twist associated signaling pathway and tumor［J］.Chinese Journal of Cancer Biotherapy,2013,20（1）:124-127. ［2］徐瑾斐.Twist2调控人类卵巢癌EMT的相关信号分子初筛［D］.厦门：厦门大学,2012. ［3］BARNES R M,FIRULLI A B.A twist of insight-the role of Twist-family bHLH factors in development［J］.Int J Dev Biol，2009,53（7）:909-924. ［4］WANG B,LINDLEY L E,FERNANDEZ-VEGA V,et al.The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells［J］.PLoS One,2012,7（7）:e41355. ［5］KIM K,PARK E Y,YOON M S,et al.The role of TWIST in ovarian epithelial cancers［J］.Korean J Pathol,2014,48（4）:283-291. ［6］CHEN Z F,BEHRINGER R R.Twist is required in head mesenchyme for cranial neural tube morphogenesis［J］.Genes Dev,1995,9（6）:686-699. ［7］张煦.Twist基因介导肿瘤细胞耐药的研究进展［J］.中国肿瘤生物治疗杂志,2012,19（5）:561-564. ZHANG X.Progress in Twist gene mediated drug resistance of tumor cells［J］.Chinese Journal of Cancer Biotherapy,2012,19（5）:561-564. ［8］CASTANON I,BAYLIES M K.A Twist in fate:evolutionary comparison of Twist structure and function［J］.Gene,2002,287（1/2）:11-22. ［9］SCHLUTH-BOLARD C,TILL M,LABALME A,et al.TWIST microdeletion identified by array CGH in a patient presenting Saethre-Chotzen phenotype and a complex rearrangement involving chromosomes 2 and 7［J］.Eur J Med Genet,2008,51（2）:156-164. ［10］MAESTRO R,DEI T A,HAMAMORI Y,et al.Twist is a potential oncogene that inhibits apoptosis［J］.Genes Dev,1999,13（17）:2207-2217. ［11］PICCININ S,TONIN E,SESSA S,et al.A "Twist box" code of p53 inactivation:twist box:p53 interaction promotes p53 degradation［J］.Cancer Cell,2012,22（3）:404-415. ［12］TENG Y,LI X.The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms［J］.Clin Exp Metastasis,2014,31（3）:367-377. ［13］MANI S A,GUO W,LIAO M J,et al.The epithelial-mesenchymal transition generates cells with properties of stem cells［J］.Cell,2008,133（4）:704-715. ［14］RANGANATHAN S,HALAGOWDER D,SIVASITHAMBARAM N D.Quercetin suppresses Twist to induce apoptosis in MCF-7 breast cancer cells［J］.PLoS One,2015,10（10）:e0141370. ［15］QIN Q,XU Y,HE T,et al.Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms［J］.Cell Res,2012,22（1）:90-106. ［16］SHARIF M N,SOSIC D,ROTHLIN C V,et al.Twist mediates suppression of inflammation by type Ⅰ IFNs and Axl［J］.J Exp Med,2006,203（8）:1891-1901. ［17］OIC D,RICHARDSON J A,YU K,et al.Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity［J］.Cell,2003,112（2）:169-180. ［18］YANG M,MAILHOT G,BIRNBAUM M J,et al.Expression of and role for ovarian cancer G-protein-coupled receptor 1 （OGR1） during osteoclastogenesis［J］.J Biol Chem,2006,281（33）:23598-23605. ［19］LO H W,HSU S C,XIA W,et al.Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression［J］.Cancer Res,2007,67（19）:9066-9076. ［20］TENG J,WANG X,XU Z,et al.HBx-dependent activation of Twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells［J］.J Cell Biochem,2013,114（5）:1097-1104. ［21］CHEN W,GAO Q,HAN S,et al.The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling［J］.Tumour Biol,2015,36（2）:973-981. ［22］WANG W,YU S,YANG X,et al.Expression and significance of twist and E-cadherin in ovarian cancer tissues［J］.Asian Pac J Cancer Prev,2013,14（2）:669-672. ［23］PEINADO H,OLMEDA D,CANO A.Snail,Zeb and bHLH factors in tumour progression:an alliance against the epithelial phenotype?［J］.Nat Rev Cancer,2007,7（6）:415-428. ［24］ECKERT M A,LWIN T M,CHANG A T,et al.Twist1-induced invadopodia formation promotes tumor metastasis［J］.Cancer Cell,2011,19（3）:372-386. ［25］BECK B,LAPOUGE G,RORIVE S,et al.Different levels of Twist1 regulate skin tumor initiation,stemness,and progression［J］.Cell Stem Cell,2015,16（1）:67-79. ［26］YIN G,ALVERO A B,CRAVEIRO V,et al.Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential［J］.Oncogene,2012,32（1）:39-49. ［27］NYBERG P,XIE L,KALLURI R.Endogenous inhibitors of angiogenesis［J］.Cancer Res,2005,65（10）:3967-3979. ［28］LI J,LIU C H,SUN Y,et al.Endothelial TWIST1 promotes pathological ocular angiogenesis［J］.Invest Ophthalmol Vis Sci,2014,55（12）:8267-8277. ［29］LIU A,HUANG C,CAI X,et al.Twist promotes angiogenesis in pancreatic cancer by targeting miR-497/VEGFA axis［J］.Oncotarget,2016,7（18）:25801-25814. ［30］LOW-MARCHELLI J M,ARDI V C,VIZCARRA E A,et al.Twist1 induces CCL2 and recruits macrophages to promote angiogenesis［J］.Cancer Res,2013,73（2）:662-671. ［31］JOHN A,TUSZYNSKI G.The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis［J］.Pathol Oncol Res,2001,7（1）:14-23. ［32］杨丽娜，吴娟，赵静，等.Twist和VEGF在上皮性卵巢癌中的表达［J］.西安交通大学学报（医学版）,2015,79（3）:341-344. YANG L N,WU J,ZHAO J,et al.Expressions of Twist and VEGF in epithelial ovarian cancer［J］.Journal of Xi’an Jiaotong University （Medical Sciences）,2015,79（3）:341-344. ［33］刘太圣.白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效及对Twist蛋白和血管内皮生长因子表达的影响［J］.中国医学前沿杂志（电子版）,2015,8（6）:168-171. LIU T S.Analysis the efifcacy of albumin-bound paclitaxel and paclitaxel liposome in the treatment of recurrent ovarian cancer and the inlfuence of expressions of Twist and VEGF［J］.Chinese Journal of the Frontiers of Medical Science （Electronic Version）,2015,8（6）:168-171. ［34］CANNISTRA S A.Cancer of the ovary［J］.N Engl J Med,2004,351（24）:2519-2529. ［35］ZHANG X,WANG Q,LING M T,et al.Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells［J］.Int J Cancer,2007,120（9）:1891-1898. ［36］LU S,YU L,MU Y,et al.Role and mechanism of Twist1 in modulating the chemosensitivity of FaDu cells［J］.Mol Med Rep,2014,10（1）:53-60. ［37］ZHAN X,FENG X,KONG Y,et al.JNK signaling maintains the mesenchymal properties of multi-drug resistant human epidermoid carcinoma KB cells through snail and twist1［J］.BMC Cancer,2013,13:180. ［38］WANG X,LING M T,GUAN X Y,et al.Identification of a novel function of TWIST,a bHLH protein,in the development of acquired taxol resistance in human cancer cells［J］.Oncogene,2004,23（2）:474-482. ［39］HOSONO S,KAJIYAMA H,TERAUCHI M,et al.Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients［J］.Br J Cancer,2007,96（2）:314-320. ［40］KAJIYAMA H,SHIBATA K,TERAUCHI M,et al.Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells［J］.Int J Oncol,2007,31（2）:277-283. ［41］WANG T,LI Y,TUERHANJIANG A,et al.Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3beta signaling pathway［J］.Oncol Lett,2014,7（4）:1102-1108.

[1]	XIANG Tianle, ZHOU Na, LI Fang, CAO Meijuan. Research Progress on Assessment Methods of 24-hour Movement Behaviors in Children [J]. Chinese General Practice, 2026, 29(06): 760-766.
[2]	WANG Lina, LEI Jingshu, LI Kuibao, WANG Ruiying, LI Xinmiao, WANG Fangfang, GUO Xiaorong, NIU Ruihao, ZHAO Wei, ZHOU Fangfang, ZHAO Jingjing, LEE CHONGYOU. Review on Inflammatory Response in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2026, 29(06): 790-801.
[3]	SHI Jiaqi, WANG Yuxin, LUO Jiani, JIANG Qi, WU Shanyu, JIN Toufeng. Factors Influencing Symptom Clusters in Patients with Gastrointestinal Cancers: a Scoping Review [J]. Chinese General Practice, 2026, 29(05): 668-675.
[4]	TIAN Ziwei, YANG Zhilan, ZHAO Huimin, ZHAI Yanping, LI Hongyan, DU Miao, JIN Yuanyuan, SONG Zeyu. Frailty in Patients with Knee Osteoarthritis: a Scoping Review [J]. Chinese General Practice, 2026, 29(05): 676-680.
[5]	CAO Xinyang, WANG Yang, JIN Hua, YU Dehua, YANG Hui, LIU Xiaoyun, XU Yanli. Factors Influencing the Development of Research Capabilities in General Practice: a Scoping Review [J]. Chinese General Practice, 2026, 29(04): 444-456.
[6]	WANG Yiheng, XU Xiaoming, XIA Yunlong, XIA Linying, HAN Xue, GUO Yongzhen, LIU Quanchi, YAN Wenjun. Progress in Pharmacotherapy of Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(03): 403-408.
[7]	JIANG Xiaorui, YAN Yuyao, WEI Jingjing, QIAO Lijie, PENG Guangcao, ZHU Mingjun. Systematic Review of Risk Prediction Models for Concurrent Heart Failure with Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(03): 393-402.
[8]	LIU Yan, YUAN Yanling, LING Rong, WANG Lanyun, SUN Li. Scoping Review of Telemedicine Application in Cardiac Rehabilitation for Coronary Heart Disease Patients [J]. Chinese General Practice, 2025, 28(36): 4640-4647.
[9]	SUN Jiaying, ZHOU Pengxiang, XIA Yu, YAN Ming, ZHOU Xinmei, WU Lingyan, TONG Yuling, ZHAO Yang, XU Zhijie. Interpretation of a Position Statement from an Italian Scientific Consortium: Medication Review and Deprescribing [J]. Chinese General Practice, 2025, 28(36): 4550-4557.
[10]	WANG Yi, CHENG Jinxiang, ZHAO Xianchao, REN Jiafeng, ZHANG Liping, DONG Menglong, LIN Zhifeng, SU Changjun. Research Progress on Drug-related Rapid Eye Movement Sleep Behavior Disorder [J]. Chinese General Practice, 2025, 28(35): 4511-4516.
[11]	LI Mingyue, TANG Haoqing, ZHENG Huixian, ZHANG Xiaotian, LIU Xiaoyun. Exploring the Concept of the Quality of Primary Health Care: a Systematic Review [J]. Chinese General Practice, 2025, 28(34): 4300-4310.
[12]	HUANG Xintao, CHEN Mo, WANG Junyu, ZHANG Chen, DENG Huisheng. Research on Education of Rural-oriented Medical Students in China: a Systematic Review [J]. Chinese General Practice, 2025, 28(34): 4290-4299.
[13]	HE Yuling, LIN Meiqun, LUO Huiyu, HUANG Wenting, JIANG Liqin, ZHU Hongyu. Systematic Review of Guidelines for the Management of Patients with Cancer Pain [J]. Chinese General Practice, 2025, 28(33): 4199-4205.
[14]	WANG Mengqi, LIANG Moxuan, LI Zeyuan, GUO Yuting, CHENG Jingmin. Effectiveness of Intermittent Fasting in Patients with Type 2 Diabetes Mellitus: a Scoping Review [J]. Chinese General Practice, 2025, 28(33): 4234-4240.
[15]	GAO Jiaxin, ZHOU Ruihan, WANG Fangfang, PANG Rizhao, ZHANG Anren. Advances in Dietary Restriction on the Regulation of Organismal Immune Function [J]. Chinese General Practice, 2025, 28(32): 4102-4109.